Skip to Content
Merck
CN

G3796

Granisetron hydrochloride

≥98% (HPLC), solid

Synonym(s):

1-Methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide hydrochloride

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C18H24N4O· HCl
CAS Number:
107007-99-8
Molecular Weight:
348.87
NACRES:
NA.77
PubChem Substance ID:
329799917
UNSPSC Code:
12352200
MDL number:
MFCD01747034

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C18H24N4O.ClH/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17;/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23);1H/t12-,13+,14-;

SMILES string

Cl.CN1[C@H]2CCC[C@@H]1C[C@@H](C2)NC(=O)c3nn(C)c4ccccc34

InChI key

QYZRTBKYBJRGJB-WQTKJZBYSA-N

assay

≥98% (HPLC)

form

solid

storage condition

desiccated

color

white to off-white

mp

284.0-290.0 °C

solubility

H2O: >10 mg/mL

originator

Roche

storage temp.

room temp

Quality Level

100

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Granisetron hydrochloride helps to block nausea/emesis and abdominal pain in irritable bowel syndrome, that is stimulated by chemotherapy.
Granisetron hydrochloride is a serotonin 5-HT3 receptor antagonist and antiemetic.

Features and Benefits

This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000276010
0000276010
0000077300
0000060827
0000060826

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Alterations of colonic sensitivity and gastric dysmotility after acute cisplatin and granisetron
Martin R, et al.
Neurogastroenterology and Motility, e13499-e13499 (2018)
Jennifer Fazzari et al.
International journal of radiation biology, 88(10), 786-790 (2012-07-25)
To test the importance of serotonin as a signaling molecule involved in the production and response of radiation-induced bystander effects. HPV-G human keratinocyte cultures were spiked with various concentrations of Granisetron or Ketanserin and subject to either 0 Gy or
Michiyasu Murakami et al.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 22(4), 905-909 (2013-11-19)
Patients with gastrointestinal cancer who were receiving moderately emetogenic chemotherapy (MEC) were switched from granisetron, a first-generation 5-hydroxytryptamine-3 receptor antagonist, to palonosetron at our hospital. In the present study, we compared effectiveness before and after switching antiemetic treatment. Among patients
H Saito et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 24(4), 1067-1073 (2012-11-03)
We evaluated the efficacy and safety of single-dose fosaprepitant in combination with intravenous granisetron and dexamethasone. Patients receiving chemotherapy including cisplatin (≥70 mg/m(2)) were eligible. A total of 347 patients (21% had received cisplatin with vomiting) were enrolled in this
Joseph A Roscoe et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30(27), 3389-3395 (2012-08-24)
We conducted a double-blind randomized clinical trial of the following four regimens for controlling delayed nausea (DN): group 1: palonosetron + dexamethasone on day 1 with prochlorperazine on days 2 and 3; group 2: granisetron + dexamethasone on day 1
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service